Insider Selling: Vir Biotechnology (NASDAQ:VIR) CAO Sells 1,829 Shares of Stock

Vir Biotechnology, Inc. (NASDAQ:VIR) CAO Brent Sabatini sold 1,829 shares of Vir Biotechnology stock in a transaction dated Monday, February 23rd. The stock was sold at an average price of $7.45, for a total transaction of $13,626.05. Following the transaction, the chief accounting officer directly owned 71,043 shares of the company’s stock, valued at approximately $529,270.35. This represents a 2.51% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Brent Sabatini also recently made the following trade(s):

• On Friday, February 13th, Brent Sabatini sold 1,530 shares of Vir Biotechnology stock. The stock was sold at an average price of $7.79, for a total transaction of $11,918.70.

Vir Biotechnology Stock Performance

NASDAQ VIR traded up $2.06 during trading on Tuesday, hitting $9.49. The stock had a trading volume of 38,240,174 shares, compared to its average volume of 1,972,225. The stock has a market capitalization of $1.32 billion, a price-to-earnings ratio of -3.00 and a beta of 1.69. Vir Biotechnology, Inc. has a one year low of $4.16 and a one year high of $10.29. The stock has a 50 day simple moving average of $6.80 and a 200 day simple moving average of $5.99.

Vir Biotechnology (NASDAQ:VIR) last released its earnings results on Monday, February 23rd. The company reported ($0.31) EPS for the quarter, beating analysts’ consensus estimates of ($0.42) by $0.11. Vir Biotechnology had a negative return on equity of 47.14% and a negative net margin of 638.88%.The firm had revenue of $64.07 million for the quarter, compared to analysts’ expectations of $19.91 million. During the same quarter in the prior year, the firm posted ($0.76) earnings per share. The company’s quarterly revenue was up 417.8% on a year-over-year basis. On average, sell-side analysts predict that Vir Biotechnology, Inc. will post -3.92 EPS for the current year.

Key Headlines Impacting Vir Biotechnology

Here are the key news stories impacting Vir Biotechnology this week:

• Positive Sentiment: Astellas strategic collaboration: Vir announced a global co‑development/co‑commercialization collaboration with Astellas for prostate cancer candidate VIR‑5500 that includes $335M upfront/near‑term payments, up to $1.37B in additional milestones, a 50/50 U.S. profit/loss split, Astellas leading U.S. commercialization and ex‑U.S. rights, plus tiered double‑digit ex‑U.S. royalties — a major de‑risking and validation event for the program. Read More.
• Positive Sentiment: Encouraging Phase 1 VIR‑5500 data: Updated trial results show a favorable safety profile and meaningful activity (reported ORR ~45% at higher doses in later cohorts), supporting the value of the asset and underpinning the Astellas deal. Read More.
• Positive Sentiment: Quarterly beat and strong revenue growth: Q4 EPS of ($0.31) beat estimates and revenue of $64.1M significantly exceeded the consensus (~$19.9M), with revenue up ~418% year‑over‑year — evidence of commercial traction and stronger near‑term financial performance. Read More.
• Positive Sentiment: Analyst upgrade: Needham raised its price target to $18 and maintained a buy rating, adding institutional validation and support for higher upside expectations. Read More.
• Neutral Sentiment: Broad media coverage and analyst commentary: Multiple outlets (Forbes, Seeking Alpha, MSN) are highlighting the deal, data and earnings beat — amplifying attention and trading volume but not adding new fundamentals. Read More.
• Neutral Sentiment: Company disclosures and materials: Earnings call transcript and slide deck provide more color on pipeline prioritization (HDV, oncology) and capital deployment plans. Read More.
• Negative Sentiment: Proposed public offering: Vir filed to sell additional shares, which can be dilutive and weigh on near‑term share price despite the cash proceeds. Read More.
• Negative Sentiment: Ongoing losses and wide negative margins: The company reported a large 2025 net loss (and very negative margins), so long‑term value depends on successful development/commercial execution and milestone/cash management. Read More.

Wall Street Analyst Weigh In

A number of analysts have weighed in on VIR shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of Vir Biotechnology in a research note on Monday, December 22nd. Raymond James Financial upgraded shares of Vir Biotechnology from an “outperform” rating to a “strong-buy” rating and set a $19.00 price target on the stock in a report on Tuesday. Needham & Company LLC raised their price target on shares of Vir Biotechnology from $14.00 to $18.00 and gave the stock a “buy” rating in a research note on Tuesday. HC Wainwright reiterated a “buy” rating and set a $15.00 price objective on shares of Vir Biotechnology in a report on Tuesday, December 30th. Finally, Barclays reissued an “overweight” rating and issued a $30.00 price objective on shares of Vir Biotechnology in a research report on Tuesday. One equities research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Vir Biotechnology has an average rating of “Moderate Buy” and a consensus price target of $19.88.

Institutional Trading of Vir Biotechnology

Several institutional investors and hedge funds have recently made changes to their positions in the company. ARCH Venture Management LLC bought a new stake in shares of Vir Biotechnology in the 2nd quarter valued at about $65,100,000. GSK plc bought a new position in shares of Vir Biotechnology during the fourth quarter valued at approximately $51,562,000. State Street Corp increased its holdings in Vir Biotechnology by 18.9% during the fourth quarter. State Street Corp now owns 6,229,555 shares of the company’s stock valued at $37,564,000 after buying an additional 988,262 shares during the period. Orbimed Advisors LLC raised its stake in Vir Biotechnology by 5.9% in the second quarter. Orbimed Advisors LLC now owns 2,380,715 shares of the company’s stock worth $11,999,000 after buying an additional 132,466 shares in the last quarter. Finally, Geode Capital Management LLC raised its stake in Vir Biotechnology by 3.6% in the fourth quarter. Geode Capital Management LLC now owns 2,328,207 shares of the company’s stock worth $14,041,000 after buying an additional 81,985 shares in the last quarter. 65.32% of the stock is currently owned by institutional investors.

Vir Biotechnology Company Profile

Vir Biotechnology, Inc is a clinical‐stage immunology company dedicated to developing therapies that prevent and treat serious infectious diseases. The company leverages a suite of proprietary technology platforms—ranging from antibody isolation and screening tools to cell‐based assays and bioinformatics—to identify and advance antiviral and antibacterial candidates. Its scientific approach centers on harnessing the human immune system through monoclonal antibodies and immunomodulatory agents.

The company’s pipeline includes product candidates targeting influenza A, COVID‐19, HIV, hepatitis B, and tuberculosis.